The acquisition will offer investment and capacities to steer the growth of Advanz Pharma, which focuses on complex medicines in Europe. Credit: Michał Parzuchowski / Unsplash.

Nordic Capital subsidiary Cidron Aida Bidco has acquired all issued and to-be-issued limited voting share capital of UK-based speciality pharmaceutical company, Advanz Pharma, for a total value of nearly $846m.

According to the deal, each Advanz Pharma shareholder will get $17.26 in cash per share of the company.

This excludes Bybrook, the former shareholder of the company who opted for the alternative offer and whose shares were swapped for Topco B Shares.

Nordic Capital Advisors partner and Healthcare head Raj Shah said: “Advanz Pharma’s vision and regional focus fully aligns with Nordic Capital’s expertise and deep knowledge of European market sectors.

“Nordic Capital will help fuel the company’s strategic growth and allow it to invest in the future pipeline and M&A activities so that even more patients can access critical medicines now and in the future.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The acquisition will offer investment and capacities to support the growth of Advanz Pharma, which focuses on complex medicines in Europe.

It could help in delivering additional cost-savings to the UK National Health Service and European healthcare systems while increasing options and global access to critical medicines.

Advanz Pharma delivers and improves the critical drugs patients depend on and facilitates sustained access while enhancing health outcomes.

Furthermore, the company’s capabilities in anti-infectives and endocrinology therapy fields and collaborations with hospital decision-makers make it an ideal partner for marketing complex treatments in Europe, Advanz Pharma noted.

Advanz Pharma CEO Graeme Duncan said: “Nordic Capital will be pivotal in helping the business through both its deep sector expertise and access to capital that will enable considerable investment in our organic and inorganic pipeline.

“This partnership will be essential in allowing us to further broaden choice for both prescribers and patients throughout the world and ensure access to the essential medicines we supply.”

The deal was executed through a court-sanctioned scheme of arrangement.